ClinicalTrials.gov
public full text
Public Domain
Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture
It has been shown in rodent models that chronic substance abuse is associated with a rigidification of cell membrane fluidity due to a change in the membrane cholesterol/phospholipids ratio. Upon substance withdrawal the membrane undergoes reequilibration of this ratio, a process resulting both in an acute and a prolonged severe withdrawal syndrome. MBM has developed a patented,phosphatidic acid-enriched phospholipid platform ("LIBERTAL"), which is supposed to facilitate the membrane fluidity recovery. The company has focused on nicotine withdrawal in smoking cessation,as primary target.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction#852623
- WITHDRAWN: Generating Structurally Diverse Therapeutic Peptides with GFlowNet#387002
- Varenicline Light Smoking Pilot#825145
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder#993267
- Study of the Effects of Mecamylamine and Varenicline in Schizophrenia#899678
Record · ID 1308510
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive